Ketamine shows promise for bipolar depression in new trial
NCT ID NCT05004896
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 22 times
Summary
This study tested four doses of intravenous ketamine in 71 adults with treatment-resistant bipolar depression. Participants received either ketamine or a sedative (midazolam) over two weeks. The goal was to see if ketamine could safely reduce depression symptoms. Results focused on changes in depression scores and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIPOLAR DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ontario Shores Centre for Mental Health Sciences
Whitby, Ontario, L1N 5S9, Canada
-
Toronto General Hospital
Toronto, Ontario, M5G 2C4, Canada
-
Toronto Western Hospital
Toronto, Ontario, M5T 2S8, Canada
Conditions
Explore the condition pages connected to this study.